Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMN-201
- Development stage
- Phase 3
- Lead developer
- Lumen Bioscience
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
**LMN-201** is an investigational oral, enteric-capsule biologic cocktail developed by Lumen Bioscience for treatment of *Clostridioides difficile* infection and prevention of recurrent infection. The fixed combination comprises three toxin B-binding single-domain antibody-derived proteins and a phage-derived endolysin, produced in separate engineered *Arthrospira platensis* spirulina strains and administered as dried non-viable biomass. The antibody components bind distinct epitopes of *C. difficile* toxin B to neutralize its host-cell toxicity, while the endolysin degrades the bacterial cell wall to lyse the pathogen locally in the gastrointestinal tract. LMN-201 is being evaluated alongside and after standard-of-care anti-*C. difficile* antibiotics in the Phase 2/3 RePreve trial. ([db.antibodysociety.org](https://db.antibodysociety.org/db0/937/))
- Other names
- C. difficile TcdB-binding proteins/endolysin combination LMN-201LMN 201LMN201LMN-201LMN-Cdiff01LMN-Cdiff-01LMN-Cdiff 01
02
Targets
TcdB (Clostridioides difficile large clostridial toxin family)Clostridioides difficile peptidoglycan
Beyond the preview
Go deeper on LMN-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMN-201.